Vigil Neuroscience Inc
NASDAQ:VIGL
Vigil Neuroscience Inc
NASDAQ:VIGL
Price:
3.49 USD
-1.41%
Updated:
May 17, 2024
P/E
Price to Earnings
Price to Earnings
-1.6
Current
-3.4
Median
27.4
Industry
Higher
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=-1.6
Market Cap
/
133m
Net Income
-82.8m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Vigil Neuroscience Inc
NASDAQ:VIGL
|
133m USD | -1.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
291.9B USD | 60.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
166.8B USD | 44.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.9B USD | 31.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.2B USD | 27.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.3B AUD | 36.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
84B USD | 173.6 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
50.3B USD | -8.4 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -57.5 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
33.1B USD | 28.3 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.7T KRW | 74.1 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
-1.6
2-Years Forward
P/E
-1.5
3-Years Forward
P/E
-2.1
You don't have any saved screeners yet
